Q-omics provides the consensus-scored C3orf38 profile across patient tissues and cancer cell-line models. C3orf38 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C3orf38 is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, C3orf38 RNA expression shows 19,552 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LIHC, and ACC as cancer lineages where C3orf38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C3orf38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C3orf38 survival associations across molecular data types. C3orf38 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C3orf38 RNA expression–survival associations across cancer types. High C3orf38 expression shows unfavorable associations in LIHC and ACC, but favorable associations in KIRC, COAD, STAD and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C3orf38 RNA expression.
This table summarizes C3orf38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C3orf38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C3orf38 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, BLCA, STAD and BRCA. The LIHC box plot shows higher C3orf38 RNA expression in tumor versus normal tissue (log2 FC = +0.564, t-test p < 0.001).
This table shows molecular features associated with C3orf38 in patient tissues and cancer cell lines. In patient samples, C3orf38 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C3orf38 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and UPPER_AERODIGESTIVE_TRACT.
